tetano
Editor, Senior Moderator
Bioinformatics. 2016 May 9. pii: btw293. [Epub ahead of print]
[h=1]A computational model to predict the immune system activation by citrus derived vaccine adjuvants.[/h] Pappalardo F[SUP]1[/SUP], Fichera E[SUP]2[/SUP], Paparone N[SUP]3[/SUP], Lombardo A[SUP]3[/SUP], Pennisi M[SUP]4[/SUP], Russo G[SUP]5[/SUP], Leotta M[SUP]6[/SUP], Pappalardo F[SUP]3[/SUP], Pedretti A[SUP]7[/SUP], De Fiore F[SUP]8[/SUP], Motta S[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]MOTIVATION:[/h] Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: enhance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants approved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limitations of the currently available licensed adjuvants.
[h=4]RESULTS:[/h] We developed a computational framework that provides a complete pipeline capable of predicting the best citrus-derived adjuvants for enhancing the immune system response using, as a target disease model, influenza A infection. In silico simulations suggested a good immune efficacy of specific citrus derived adjuvant (Beta Sitosterol) that was then confirmed in vivo.
[h=4]AVAILABILITY:[/h] The model is available visiting the following URL: http://vaima.dmi.unict.it/AdjSim CONTACT: francesco.pappalardo@unict.it SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
? The Author (2016). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
PMID: 27162187 [PubMed - as supplied by publisher]
[h=1]A computational model to predict the immune system activation by citrus derived vaccine adjuvants.[/h] Pappalardo F[SUP]1[/SUP], Fichera E[SUP]2[/SUP], Paparone N[SUP]3[/SUP], Lombardo A[SUP]3[/SUP], Pennisi M[SUP]4[/SUP], Russo G[SUP]5[/SUP], Leotta M[SUP]6[/SUP], Pappalardo F[SUP]3[/SUP], Pedretti A[SUP]7[/SUP], De Fiore F[SUP]8[/SUP], Motta S[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]MOTIVATION:[/h] Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: enhance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants approved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limitations of the currently available licensed adjuvants.
[h=4]RESULTS:[/h] We developed a computational framework that provides a complete pipeline capable of predicting the best citrus-derived adjuvants for enhancing the immune system response using, as a target disease model, influenza A infection. In silico simulations suggested a good immune efficacy of specific citrus derived adjuvant (Beta Sitosterol) that was then confirmed in vivo.
[h=4]AVAILABILITY:[/h] The model is available visiting the following URL: http://vaima.dmi.unict.it/AdjSim CONTACT: francesco.pappalardo@unict.it SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
? The Author (2016). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
PMID: 27162187 [PubMed - as supplied by publisher]